• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

pSivida and Nicox partner to develop sustained-release IOP drug for glaucoma patients

October 10, 2017 By Sarah Faulkner

pSivida, NicoxpSivida (NSDQ:PSDV) and Nicox (EPA:COX) said today that the companies are collaborating to develop a sustained-release drug to lower intraocular pressure in people with glaucoma or ocular hypertension.

The deal combines pSivida’s bioerodible sustained-release drug delivery system with Nicox’s nitric oxide-donating compounds.

According to the agreement, pSivida is responsible for initial development activities. Nicox is slated to give the company undisclosed sums for its work developing ocular insert formulation of Nicox’s NO-donating product candidates.

Nicox will also make additional payments for incremental development activities for each product candidate selected by Nicox to progress into development, the companies said. Intellectual property from the collaboration will be jointly-owned and the companies plan to negotiate a separate license deal for any product candidate that they want to commercialize.

“We have strong pre-clinical data demonstrating the IOP lowering effect of our novel stand-alone NO donors, such as our lead NCX 667, and believe that their profile makes them product candidates for potential sustained release delivery,” Michael Bergamini, Nicox’s EVP & chief scientific officer, said in prepared remarks.

“The bioerodible technology in development by pSivida, combined with their proven success in developing sustained delivery devices for the eye, puts them at the forefront of this exciting area.”

“Nicox’s NO-donating research platform has been validated in both pre-clinical and human studies for the reduction of IOP,” pSivida’s president & CEO, Nancy Lurker, added.

“Combining this novel approach to IOP lowering with our bioerodible, sustained delivery device could offer a unique therapy alternative or adjunct to existing therapies to lower IOP in order to help prevent the development and progression of glaucoma.”

See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif.

Filed Under: Business/Financial News, Featured, Optical/Ophthalmic, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: nicox, pSivida Corp.

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS